Shopping Cart
- Remove All
- Your shopping cart is currently empty
FMK-MEA is a potent and selective inhibitor of p90 Ribosomal S6 Kinase (RSK).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,270 | 10-14 weeks | |
50 mg | $2,980 | 10-14 weeks | |
100 mg | $4,000 | 10-14 weeks |
Description | FMK-MEA is a potent and selective inhibitor of p90 Ribosomal S6 Kinase (RSK). |
In vitro | Treatment with FMK-MEA, a water-soluble derivative of fmk, effectively inhibits RSK2 kinase activity across a range of highly invasive human cancer cell lines, including 212LN, M4e, A549, and SKBR3. This RSK-specific inhibitor significantly reduces RSK2 activity in A549 cells, as evidenced by decreased phosphorylation levels of Ser-386, thereby diminishing their invasive capabilities. |
In vivo | FMK-MEA administration at a dosage of 80 mg/kg/day via intraperitoneal injection over 16 days in xenograft nude mice with highly metastatic M4e cells does not alter the size or proliferation rate of the primary tumor. However, it significantly reduces lymph node (LN) metastasis. |
Molecular Weight | 399.46 |
Formula | C21H26FN5O2 |
Cas No. | 1414811-15-6 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.